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5WERNER SIEGHART: GABAA RECEPTORS IN THE BRAIN...
First of all I would like to thank the Hungarian Academy of Sciences for 
electing me as an Honorary Member and I would especially like to thank Peter 
Somogyi and all those who supported him in proposing me for this election. 
I am very honored by this distinction and will continue to support Hungarian 
Science to the best of my abilities.
In this lecture I will explain why I entered GABAA receptor research, why 
I stayed in this fi eld, will mention some of my major scientifi c contributions, 
and will provide you with an up-to-date overview of our current knowledge on 
the structure, pharmacology and function of GABAA receptors. At the end of 
my presentation I hope to have convinced you that GABAA receptors are really 
exciting targets for the development of clinically important drugs.  
The fi rst visualization of neurons was achieved by Camillo Golgi in 1873. 
He soaked brain tissue with silver chromate, looked through a microscope, 
and identifi ed pyramidal shaped neurons with large and heavily branched 
dendritic trees and thin and weakly or unbranched axons. The dendrites collect 
information from thousands of other neurons that can come as excitation 
(depolarization), or inhibition (hyperpolarization). If the excitatory input 
overcomes the inhibitory input as well as a certain threshold of excitation at 
the axon initial segment, the neuron fi res and propagates its excitation via an 
action potential to many other neurons. At the synapses, the contact sites to 
other neurons, action potentials elicit the release of a chemical substance, a 
neurotransmitter, which diffuses through the synaptic cleft that separates 
the synapse from the postsynaptic neuron. At the postsynaptic membrane, 
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the neurotransmitter interacts with a receptor and by that elicits an opening 
of an ion channel. The opening of a sodium channel causes an excitation of the 
postsynaptic neuron, the opening of a chloride channel an inhibition. Again 
the neuron sums up all information transmitted via multiple synapses and fi res 
if excitation is strong enough and above the threshold of excitation of the neu-
ron. Information processing - in the form of making decisions on whether 
some information is suffi ciently strong and important to be further propagated 
to the brain or within the brain - thus occurs at each individual neuron and 
involves multiple pieces of information via inputs from different other neurons. 
My involvement in GABAA receptor research started in 1978, when 
I returned from my two years’ postdoctoral research in the lab of Paul 
Greengard at the Department of Pharmacology, Yale University, Connecticut, 
USA, to the University Clinic of Psychiatry, University of Vienna, Austria. 
Although I had been scientifi cally extremely successful during my time as a 
postdoc with Paul Greengard by publishing a total of 8 papers in scientifi c 
journals and by demonstrating that protein phosphorylation is involved in 
secretion1,2 and that Ca2+ and cAMP regulate the phosphorylation of the same 
nerve-specifi c proteins3, I felt that I could not continue protein phosphorylation 
research at the University Clinic of Psychiatry because I needed a topic of in-
terest for psychiatrists. Investigating the “benzodiazepine receptors” seemed 
to be such a topic. Benzodiazepines, such as chlordiazepoxide or diazepam, 
had been introduced into therapeutic use in the 1960´s, and due to their 
1 Sieghart W, Theoharides ThC, Alper SL, Douglas WW, and Greengard P (1978) Calcium 
dependent protein phosphorylation during secretion by exocytosis in the mast cell. Nature 275, 
329-331.
2 Theoharides ThC, Sieghart W, Greengard P, and Douglas WW. (1980) Antiallergic drug 
cromolyn may inhibit histamine secretion by regulating phosporylation of a mast cell protein. 
Science 207, 80-82.
3 Sieghart W, Forn J, and Greengard P (1979) Calcium and cyclic AMP regulate the 
phosphorylation of the same two membrane-associated proteins specifi c to nerve tissue. Proc 
Natl Acad Sci, USA 76, 2475-2479.
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anxiolytic, anticonvulsant, muscle relaxant, and sedative hypnotic properties, 
soon belonged to the most heavily prescribed drugs in current therapeutic use. 
These receptors for sure were of interest for psychiatrists. 
In 1975, Willi Haefely, the former director of research at the pharmaceutical 
company Hoffmann la Roche, which marketed the benzodiazepines, 
proposed that the action of benzodiazepines might be associated with GABAA 
(γ-aminobutyric acid type A) receptors. GABAA receptors are the ma-
jor inhibitory neurotransmitter receptors in the brain and can be inhibited 
by bicuculline, in contrast to GABAB receptors, that are G-protein coupled 
receptors with a different structure, function, and pharmacology. 
In 1977, a high affi nity benzodiazepine binding site was identifi ed in 
brain membranes4,5 which exhibited all properties one would expect from the 
benzodiazepine receptors. Several labs started immediately to investigate these 
novel binding sites and their properties, and this binding site was also investigated 
in the lab to which I returned6. I was well aware of these binding studies, but at 
the beginning was only marginally involved because I rather wanted to identify 
the “benzodiazepine receptor”. I therefore was quite excited when Manfred 
Karobath, the head of the laboratory at that time, returned from a scientifi c 
meeting where he learned from Hanns Möhler, that [3H]fl unitrazepam, 
which can be used as a benzodiazepine receptor ligand in reversible binding 
studies, irreversibly binds to these receptors under irradiation with UV light7. 
I immediately started with the respective experiments and incubated brain 
4 Möhler H, and Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous 
system. Science 198, 849-851
5 Braestrup C, and Squires RF (1977) Specifi c benzodiazepine receptors in rat brain characterized 
by high-affi nity [3H]diazepam binding. Proc Natl Acad Sci USA 74, 3805-3809.
6 Karobath M, and Sperk G (1979) Stimulation of benzodiazepine receptor binding by gamma-
aminobutyric acid. Proc Natl Acad Sci USA 76, 1004-1006.
7 Möhler H, Battersby MK, Richards JG (1980) Benzodiazepine receptor protein identifi ed and 
visualized in brain tissue by a photoaffi nity label. Proc Natl Acad Sci USA 77, 1666-1670.
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membranes with [3H]fl unitrazepam and irradiated the samples with UV light. 
For these experiments I used membranes from cerebellum and hippocampus, 
because there were fi rst hints that benzodiazepine receptors in cerebellum 
and hippocampus might be different. I then solubilized the membranes with 
sodium dodecylsulfate (SDS) and subjected the proteins to SDS-polyacrylamide 
gel electrophoresis and fl uorography. Using this technique, the many thousand 
proteins of the membranes are separated from each other according to their 
molecular mass, and only those proteins can be visualized, that had been 
irreversibly labeled by [3H]fl unitrazepam. The very fi rst experiments I did 
were already extremely exciting: in cerebellum a single protein with apparent 
molecular mass of 51 kDa was photolabled by [3H]fl unitrazepam, whereas in 
hippocampus not only this 51kDa protein, but at least one more protein with 
apparent molecular mass 55 kDa was labeled8 (Fig 1). All these proteins were 
associated with benzodiazepine receptors, because irreversible labeling by [3H]
fl unitrazepam could be blocked by diazepam. All these proteins were associated 
with a GABAA receptor, because their photolabeling with [3H]fl unitrazepam 
could be enhanced by GABA and this enhancement could be blocked by 
bicuculline. Finally, I used the triazolopyridazine Cl 218872, one of the fi rst 
compounds that exhibited a higher potency for inhibition of [3H]fl unitrazepam 
binding in cerebellum than in hippocampus, and demonstrated that Cl 218872 
completely inhibited photolabeling of the protein with 51 kDa in cerebellum as 
well as in hippocampus, but only weakly inhibited photolabeling of the other 
proteins in hippocampus. These results for the fi rst time provided evidence for 
a molecular heterogeneity of GABAA receptors and confi rmed the hypothesis, 
that benzodiazepine receptors are closely associated with GABAA receptors8. 
8 Sieghart W, and Karobath M (1980) Molecular heterogeneity of benzodiazepine receptors. 
Nature 286, 285-287.
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I was excited, the reviewers were excited, and the manuscript was rapidly 
published in “Nature”. My excitement, however, soon disappeared when it 
became clear that some infl uential scientists in the fi eld could not reproduce 
my data. They simply could not generate the high resolution SDS-gels I had 
learned to generate in the lab of Paul Greengard, and thus, could not separate 
the different photolabeled proteins in the hippocampus. I was desperate and 
asked all people who could not reproduce my data to come to my lab and to 
learn how to do that, and I promised to withdraw the paper if they then would 
not be able to reproduce the data in their own lab. Of course, nobody came to 
learn the technique, and I thus spent the next 8 years proving that I was right. 
Figure 1: Structural formula of fl unitrazepam and Cl 218872, and molecular heterogeneity of benzodiazepine 
receptors. Figure modifi ed from Ref 8. 
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I improved the resolution of my gels, identifi ed additional photolabeled 
proteins9 and studied their regional distribution and postnatal development10,11 
which was distinct for each protein and different in different brain regions. In 
addition, I used several proteases and investigated the photolabeled fragments. 
The fragment pattern was different in cerebellum and hippocampus12,13. 
I did a much more extensive pharmacology of the photolabeling process just 
to fi nd that the potency of the various benzodiazepine site ligands for the 
inhibition of irreversible labeling of the different proteins corresponded to that 
observed in reversible binding studies: ligands that exhibited the same affi nity 
for benzodiazepine receptors in cerebellum and hippocampus exhibited the 
same potency for inhibition of irreversible [3H]fl unitrazepam binding to the 
different proteins, and ligands with higher affi nity for receptors in cerebellum 
also exhibited a higher potency for inhibiting photolabeling of the 51 kDa 
protein, than of the proteins with higher molecular masses14. I treated the 
photolabeled proteins with various glycosidases to remove all sugar chains of 
possible different length. The molecular mass of all photolabled proteins was 
reduced by this treatment, but the difference in the apparent mass of proteins 
in the hippocampus was still there15.
9 Sieghart W, and Drexler G (1983) Irreversible binding of [3H]fl unitrazepam to different proteins 
in various brain regions. J Neurochem 41, 47-55.
10 Sieghart W, and Mayer A (1982) Postnatal development of proteins irreversibly labeled by [3H]
fl unitrazepam. Neurosci Letters 31, 71-74.
11 Eichinger A, and Sieghart W (1986) Postnatal development of proteins associated with different 
benzodiazepine receptors. J Neurochem 46, 173-180.
12 Eichinger A, and Sieghart W (1985) Differential degradation of different benzodiazepine 
binding proteins by incubation of membranes from cerebellum or hippocampus with trypsin. 
J Neurochem 45, 219-226.
13  Sieghart W, Eichinger A, and Zezula J (1987) Comparison of tryptic peptides of benzodiazepine 
binding proteins photolabeled with [3H]fl unitrazepam or [3H]Ro15-4513. J Neurochem 48, 1109-1114.
14 Sieghart W, Mayer A, and Drexler G (1983) Properties of [3H]fl unitrazepam binding to different 
benzodiazepine binding proteins. Eur J Pharmacol 88, 291-299.
15 Sieghart W, and Fuchs K (1988) Modifi cation of the apparent molecular weight of different 
benzodiazepine binding proteins from rat brain membranes by various endoglycosidases. 
Neurosci Letters 86, 213-218.
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In the meantime, two other groups were able to reproduce my data16,17 
and I became more relaxed. Nevertheless, I was relieved when the groups 
of Peter Seeburg and Eric Barnard published the fi rst cloning of GABAA 
receptors18. Following the fi rst purifi cation of GABAA receptors from 
bovine brain by Erwin Sigel19, two homologous subunits (α, β) were cloned, 
their putative transmembrane structure was determined (large N-terminal 
extracellular domain, four transmembrane domains (TMs), large intracellular 
loop between TM3 and TM4, short extracellular C-terminal domain) and it 
was demonstrated that only a combination of these subunits could produce a 
GABA activated chloride channel. One year later, the group of Peter Seeburg 
published the existence of several different homologous α subunits (α1, α2, α3) 
and the combination of these α subunits with the β subunit generated distinct 
receptors20. So 8 years after our publication in Nature, the heterogeneity 
of GABAA receptors had fi nally been confi rmed. Again, one year later, the 
group of Peter Seeburg demonstrated that besides α and β subunits, a third 
subunit, a γ subunit, is required to generate GABAA receptors that also could 
be modulated by benzodiazepines21. These data thus fi nally confi rmed the 
conclusion that benzodiazepine receptors are not only closely associated with 
16 Lippa AS, Garrett KM, Tabakoff B, Beer B, Wennogle LP, Meyerson LR (1985) Heterogeneity 
of brain benzodiazepine receptors: effects of physiological conditions. Brain Res Bull 14, 189-195.
17  Hebebrand J, Friedl W, Unverzagt B, Propping P (1986) Benzodiazepine receptor subunits in 
avian brain. J Neurochem 47, 790-793.
18 Schofi eld PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, Rhee LM, 
Ramachandran J, Reale V, Glencorse TA et al. (1987) Sequence and functional expression of the 
GABAA receptor shows a ligand-gated receptor super-family. Nature 328, 221-227.
19 Sigel E, Mamalaki C, Barnard EA (1982) Isolation of a GABA receptor from bovine brain using 
a benzodiazepine affi nity column. FEBS Lett 147, 45-48.
20 Levitan ES, Schofi eld PR, Burt DR, Rhee LM, Wisden W, Köhler M, Fujita N, Rodriguez 
HF, Stephenson A, Darlison MG, et al., (1988) Structural and functional basis for GABAA 
receptor heterogeneity. Nature 335, 76-79.
21 Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofi eld PR, Seeburg 
PH (1989) Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. 
Nature 338, 1491-1497.
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GABAA receptors, but represent allosteric binding sites at at least some of these 
receptors. 
A total of 6α, 3β, 3γ, δ, ε, π, θ, and 3 ρ subunits, as well as several 
alternatively spliced isoforms of some of these subunits were then cloned from 
the mammalian brain in the subsequent years22. Within a group (α, β, γ, δ, ε, π, 
θ, ρ) the subunits exhibited a homology of about 70%, in between the groups, 
the homology was about 30%. The homology of GABAA receptor subunits 
to subunits of other members of ligand gated ion channels (nACh receptors, 
glycine receptors, 5-HT3 receptors) was about 20%. 
The amino acid sequences of the cloned GABAA receptor subunits allowed 
to generate receptor subtype-selective antibodies by using subtype-specifi c 
amino acid sequences for the immunizing of rabbits. These fi rst subunit-specifi c 
antibodies were used to demonstrate that the various proteins photolabeled by 
[3H]fl unitrazepam were various α subunit types23. After Richard Olsen had 
demonstrated that [3H]muscimol can be used as a photoaffi nity label for the 
GABA site of GABAA receptors, we also used this new affi nity label and with 
the help of subunit-specifi c antibodies demonstrated that the different proteins 
photolabeled by [3H]muscimol were various β-subunits of GABAA receptors24. 
At that time, Hanns Möhler asked me to investigate a new photolabel of 
GABAA receptors (the imidazobenzodiazepine Ro 15-4513) that seemed to have 
peculiar properties. When we investigated this photolabel in cerebellum and 
hippocampus, it became clear that [3H]Ro 15-4513 was able to irreversibly label 
not only the 51 kDa protein in cerebellum, similar to [3H]fl unitrazepam, but 
22 Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA (2004) Analysis of the set of GABAA 
receptor genes in the human genome. J Biol Chem 279, 41422-41435.
23  Fuchs K, Möhler H, and Sieghart W (1988) Various proteins from rat brain, specifi cally 
and irreversibly labeled by [3H]fl unitrazepam, are distinct alpha subunits of the GABA-
benzodiazepine receptor complex. Neurosci Letters 90, 314-319.
24 Fuchs K, and Sieghart W (1989) Evidence for the existence of several different α- and β-subunits 
of the GABA-benzodiazepine receptor complex from rat brain. Neurosci Letters 97, 329-333.
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also an additional protein with apparent molecular mass 56 kDA25,26. Several 
years later, the α6 subunit of GABAA receptors was cloned and [3H]Ro 15-4513 
was demonstrated to bind to receptors containing this subunit27. Using our 
subsequently generated α6-selective antibodies, we demonstrated that this 56 
kDa protein represents the α6 subunit of GABAA receptors that is located 
more or less exclusively in cerebellar granule cells. 
To further investigate the heterogeneity of GABAA receptors, and 
to determine their subunit composition in vivo, my group generated large 
amounts of subunit-selective antibodies for synthesizing immunoaffi nity 
columns. These columns allowed to enrich GABAA receptors containing 
the respective subunit and to determine their subunit composition. We for 
the fi rst time demonstrated that the “type 1 benzodiazepine receptors” that are 
especially enriched in the cerebellum represent receptors containing the α1, 
a β and a γ2 subunit, and that the “type 2 benzodiazepine receptors” enriched 
in the hippocampus, consisted of α2 or α3 subunits together with a β and a γ2 
subunit28. Whenever we generated antibodies against a novel subunit, these 
antibodies were used to purify receptors containing these subunits and to 
25 Möhler H, Sieghart W, Richards JG, and Hunkeler W (1984) Photoaffi nity labeling of 
benzodiazepine receptors with a partial inverse agonist. Eur J Pharmacol. 102, 191-192.
26 Sieghart W, Eichinger A, Richards JG, and Möhler H (1987) Photoaffi nity labeling of 
benzodiazepine receptor proteins with the partial inverse agonist [3H]Ro15-4513; a biochemical 
and autoradiographic study. J Neurochem 48, 46-52.
27 Lüddens H, Pritchett DB, Köhler M, Killisch I, Keinänen K, Monyer H, Sprengel R, Seeburg 
PH (1990) Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature 
346, 648-651.
28 Zezula J, and Sieghart W (1991) Isolation of type I and type II GABAA-benzodiazepine receptors 
by immunoaffi nity chromatography. FEBS-Letters 284, 15-18.
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determine their subunit composition29,30,31,32,33. It soon became clear that there 
is an enormous heterogeneity of GABAA receptors in the brain: antibodies 
specifi c for a single α or β subunit type were able to co-purify most if not all 
other subunits, suggesting that there must be at least 2 α and 2 β subunits in 
GABAA receptors. In contrast, antibodies specifi c for a γ subunit co-purifi ed 
all subunits except δ subunits, and antibodies against δ-subunits purifi ed all 
subunits except γ subunits31, 32 , 34, 35. So γ and δ subunits seem not to occur 
together in the same receptor type and thus, seem to be present only once 
within GABAA receptors. All these results were confi rmed by other groups. 
Combined with the fi nding of the group of Eric Barnard, that GABAA 
receptors are composed of 5 subunits that form a central chloride ion channel36, 
it is now generally accepted that most of the GABAA receptors are composed 
of 2α, 2β, and one γ or δ subunit. My group was the fi rst that not only 
determined the subunit composition, but also the subunit arrangement within 
29 Zezula J, Fuchs K, and Sieghart W (1991) Separation of α1-, α2- and α3-subunits of the GABAA-
benzodiazepine receptor complex by immunoaffi nity chromatography. Brain Res 563, 325-328.
30 Kern W, and Sieghart W (1994) Polyclonal antibodies directed against an epitope specifi c 
for the α4-subunit of GABAA receptors identify a 67 kDa protein in rat brain membranes. J 
Neurochem 62, 764-769.
31 Tögel M, Mossier B, Fuchs K, and Sieghart W (1994) GABAA receptors displaying association 
of γ3-subunits with β2/3- and different α-subunits exhibit unique pharmacological properties. 
J Biol Chem 269, 12993-12998.
32 Mossier B, Tögel M, Fuchs K, and Sieghart W (1994) Immunoaffi nity purifi cation of 
γ-aminobutyric acidA (GABAA) receptors containing γ1-subunits. Evidence for the presence 
of a single type of γ-subunit in GABAA receptors. J Biol Chem 269, 25777-25782.
33 Bencsits E, Ebert V, Tretter V, and Sieghart W (1999) A signifi cant part of native 
γ-aminobutyric acidA receptors containing α4 subunits do not contain γ or δ subunits. J Biol 
Chem 274, 19613-19616. 
34 Jechlinger M, Pelz R, Tretter V, Klausberger T, and Sieghart W (1998) Subunit composition 
and quantitative importance of heterooligomeric receptors: GABAA receptors containing α6 
subunits. J Neurosci 18, 2449-2457.
35 Pöltl A, Hauer B, Fuchs K, Tretter V, Sieghart W (2003) Subunit composition and quantitative 
importance of GABAA receptor subtypes in the cerebellum of mouse and rat. J Neurochem 87, 
1444-1455.
36 Nayeem N, Green TP, Martin IL, Barnard EA (1994) Quaternary structure of the native 
GABAA receptor determined by electron microscopic image analysis. J Neurochem 62, 815-818.
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GABAA receptors: these pentameric receptors are composed of alternating 
α and β subunits connected by a γ subunit37. The subunit composition and 
arrangement of receptors containing ε, θ, or π subunits currently is not clear, 
but ρ subunits seem to be able to form homo-oligomeric receptors, or hetero-
oligomeric receptors with other ρ subunits. 
Our antibodies, of course, were also used for immunohistochemical 
studies. The fi rst study was performed together with the group of Hans 
Lassmann in Vienna, and demonstrated a differential regional distribution of 
α1, α2, and α3 subunits in the rat brain, further supporting the heterogeneity 
of GABAA receptors38. Peter Somogyi became alerted by this study and asked 
whether he could obtain the antibodies. I provided the antibodies and soon was 
very excited when I learned that especially the antibody against the α1 subunit 
was excellent and suitable for electron microscopy. This was the starting 
point of a long and prosperous collaboration with Peter Somogyi and Zoltan 
Nusser, and of a series of landmark papers published together. Using electron 
microscopic techniques these papers for the fi rst time demonstrated a synaptic 
co-localization of α1 and β2/3 and γ2 subunits39,40, that the α6 subunit of 
GABAA receptors is concentrated in both inhibitory and excitatory synapses on 
cerebellar granule cells41, that different GABAA receptor subunits can exhibit 
37 Tretter V, Ehya N, Fuchs K, and Sieghart W (1997) Stoichiometry and assembly of a 
recombinant GABAA receptor subtype. J Neurosci 17, 2728-2737.
38 Zimprich F, Zezula J, Sieghart W, and Lassmann H (1991) Immunohistochemical localization 
of the α1-, α2- and α3-subunit of the GABAA receptor in the rat brain. Neurosci Letters 127, 125-
128.
39 Nusser Z, Roberts DBJ, Baude A, Richards JG, Sieghart W, and Somogyi P (1995) 
Immunocytochemical localization of the α1 and β2/3 subunits of the GABAA receptor in 
relation to specifi c GABAergic synapses in the dentate gyrus. Eur J Neurosci 7, 630-646. 
40 Somogyi P, Fritschy JM, Benke D, Roberts JDB, and Sieghart W (1996) The γ2 subunit of the 
GABAA receptor is concentrated in synaptic junctions containing the α1 and β2/3 subunits in 
hippocampus, cerebellum and globus pallidus. Neuropharmacol 35, 1425-1444.
41 Nusser Z, Sieghart W, Stephenson FA, and Somogyi P (1996) The α6 subunit of the GABAA 
receptor is concentrated in both inhibitory and excitatory synapses on cerebellar granule cells. 
J Neurosci 16, 103-114. 
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a differential subcellular distribution on hippocampal pyramidal neurons42, and 
that in addition to synaptic receptors there are also extrasynaptic receptors in 
cerebellar granule cells43. Whereas γ2-containing receptors could be found at 
synapses as well as extrasynaptically, δ-containing receptors seem to be located 
exclusively extrasynaptically. 
Other researchers asked for our antibodies too, and this resulted in a se-
ries of collaborative studies on the localization of various GABAA receptor 
subunits in different brain regions and cell types, their changes in development 
and under the infl uence of ethanol. Such studies also provided important 
information on the co-localization of GABAA receptor and glycine receptor 
subunits at synapses in the spinal cord44 and on subunit partnerships within 
GABAA receptors, indicating that α6 and δ subunits are strongly associated 
with each other45. Other collaborations indicated that the neurosteroid 
sensitivity of δ subunit knockout mice is signifi cantly decreased, suggesting 
that neurosteroids predominantly act via δ-containing receptors46.
In 1996 I was asked by Günther Sperk whether he could obtain our 
antibodies for investigating the regional distribution of GABAA receptor 
42 Nusser Z, Sieghart W, Benke D, Fritschy JM, and Somogyi P (1996) Differential synaptic 
localization of two major γ-aminobutyric acid type A receptor α subunits on hippocampal 
pyramidal cells. Proc Natl Acad Sci USA 93, 11939-11944. 
43 Nusser Z, Sieghart W, and Somogyi P (1998) Segregation of different GABAA receptors to 
synaptic and extrasynaptic membranes of cerebellar granule cells. J Neurosci 18, 1693-1703.
44 Todd AJ, Watt C, Spike RC, and Sieghart W (1996) Co-localization of GABA, glycine and 
their receptors at synapses in the rat spinal cord. J Neurosci 16, 974-982. 
45  Jones A, Korpi ER, McKernan RM, Nusser Z, Pelz R, Mäkelä R, Mellor JR, Pollard S, Bahn 
S, Stephenson RA, Randall AD, Sieghart W, Somogyi P, Smith AJH, and Wisden W (1997)  
Ligand-gated ion channel subunit partnerships: GABAA receptor α6 subunit gene inactivation 
inhibits δ subunit expression. J Neurosci 17, 1350-1362.
46 Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi -PZ, Lagenaur C, Tretter 
V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, 
DeLorey TM, Olsen RW, and Homanics GE (1999) Attenuated sensitivity to neuroactive 
steroids in γ-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci 
USA 96, 12905-12910. 
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Figure 2: Regional distribution of 13 GABAA receptor subunits in the rat brain. Figure taken from Ref 49.
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subunits in the rat brain. Since Peter Somogyi was not interested in a systematic 
investigation of the regional distribution of subunits, I started the collaboration 
with Günther Sperk. From several hundred subunit-specifi c antibodies sent 
to him he selected the best ones for immunohistochemistry of 13 different 
subunits. We fi rst published the differential distribution of the 13 subunits in 
hippocampus and the changes in this distribution occurring during epileptic 
seizures47,48. Later on we published the distribution of these 13 subunits in the 
whole rat brain49 (Fig 2) and recently in the whole mouse brain50.  
In 2001 the crystal structure of the acetylcholine binding protein 
(AChBP) was published by the groups of Titia Sixma and Guus Smit51. This 
protein forms homopentamers, and is secreted into the synaptic cleft of a snail 
where it binds acetylcholine. Due to its structural homology to the extracellular 
domain of nicotinic acetylcholine receptors this protein is also homologous 
to the extracellular domain of GABAA receptors and could thus be used as a 
template for modelling this extracellular receptor domain.  Margot Ernst in 
my lab, supported by an undergraduate student and Stefan Boresch from the 
Institute of Theoretical Chemistry and Structural Biology in Vienna, was one 
of the fi rst to model the extracellular domain of GABAA receptors by using the 
47 Sperk G, Schwarzer C, Tsunashima K, Fuchs K, and Sieghart W (1997) GABAA receptor 
subunits in the rat hippocampus I: Immunocytochemical distribution of thirteen subunits. 
Neurosci 80, 987-1000. 
48 Schwarzer C, Tsunashima K, Wanzenböck C, Fuchs K, Sieghart W, and Sperk G (1997) 
GABAA receptor subunits in the rat hippocampus II: Altered distribution in kainic acid-induced 
temporal lobe epilepsy. Neurosci 80, 1001-1017.
49 Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G (2000) GABAA receptors: 
immunocytochemical distribution of 13 subunits in the adult rat brain. Neurosci 101, 815-850.
50 Hörtnagl, H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G (2013) Patterns 
of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neurosci 
236, 345-372
51 Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK 
(2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of 
nicotinic receptors. Nature 411, 269-276.
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crystal structure of the AChBP as a template52. She also carefully analyzed the 
homologies of the different parts of the AChBP and GABAA receptor structure 
and provided some guidelines on the reliabilities of the different parts of the 
model structure. Together with mutagenesis studies from a variety of authors 
and studies using concatenated subunits of Erwin Sigel, these data for the fi rst 
time identifi ed the absolute arrangement of subunits within GABAA receptors 
and the location of the two GABA binding sites at the two β+α− interfaces and 
that of the benzodiazepine binding site at the α+γ− interface (Fig3A). 
At that time it was already clear that GABAA receptors are chloride ion 
channels that can be opened by GABA and can be allosterically modulated 
by a large variety of pharmacologically and clinically important drugs, such 
as benzodiazepines, barbiturates, neuroactive steroids, anesthetics, convulsants 
and many other compounds53. All these compounds seem to act via distinct 
binding sites at GABAA receptors. Whereas benzodiazepines can only modulate 
ongoing GABAergic activity and cannot directly activate GABAA receptors in 
the absence of GABA, most of these other compounds at low concentrations 
allosterically modulate GABA-induced ion fl ux, but at higher concentrations 
are also able to directly activate these receptors in the absence of GABA. These 
compounds thus exhibit a much higher toxicity than benzodiazepines. In 
addition, depending on the structure of the benzodiazepines, their binding to 
the benzodiazepine binding site can induce or stabilize different conformations 
of the receptor that can either enhance or reduce GABA-induced ion fl ux. 
A third group of ligands bind to the benzodiazepine site but do not change 
GABA-induced currents. These compounds, however, can block the effect of 
other ligands acting via the benzodiazepine binding site53. Given the rich and 
52 Ernst M, Brauchart D, Boresch S, and Sieghart W (2003) Comparative modeling of GABAA 
receptors: limits, insights, future developments. Neurosci 119, 933-943.
53 Sieghart W. (1995) Structure and pharmacology of GABAA receptor subtypes. Pharmacol Rev 
47, 181-234. 
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complex pharmacology of GABAA receptors, I always wondered how a single 
receptor could accomodate so many binding sites, and where these binding sites 
might all be located. 
The answer again came from modelling studies. In 2005, Nigel Unwin 
published the structure of not only the extracellular domain but also of the 
transmembrane domains of the nACh receptor from cryo-electronmicroscopic 
studies. This structure was then used as a template for modelling the GABAA 
receptor extracellular and transmembrane domains by Margot Ernst54 (Fig3C). 
In doing that she soon realized that there are quite a few solvent accessible 
spaces within the GABAA receptor. In the extracellular domain of the 
pentameric receptor, the fi ve subunit interfaces are obviously solvent accessible. 
Each subunit exhibits four transmembrane helices and at the interface between 
two such four-helix bundles, between helix 1 of the one subunit and helix 3 of 
the neighbouring subunit, another solvent accessible space is located. A third 
type of solvent accessible spaces is located within each four helix bundle, and 
of course, the ion channel itself is solvent accessible (Fig3B). This total of 16 
solvent accessible spaces (pockets) presumably are used for conformational 
changes of the receptors, but on binding of compounds within these pockets, 
the compounds might induce or stabilize a certain confomational state of the 
receptor that enhances or reduces GABA-induced ion fl ux. In addition, it 
is conceivable that the synergistic effect of two ligands binding in different 
pockets could also directly activate the receptor in the absence of GABA. These 
data were consistent with mutagenesis studies identifying amino acid residues 
important for the binding or transduction of the effects of inhalation- or 
intravenous-anesthetics and of steroids. Recently, the concept of the existence 
of binding sites for steroids and anesthetics within the transmembrane domains 
54  Ernst M, Bruckner S, Boresch S, and Sieghart W. (2005) Comparative models of GABAA 
receptor extracellular and transmembrane domains: important insights in pharmacology and 
function. Mol Pharmacol 68, 1291-1300.
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Figure 3: Model structure of the GABAA receptor. (A) Model of the extracellular domain of the GABAA 
receptor, giving the absolute arrangement for α1, β2, and γ2 containing receptors, the view is from extracellular. 
The + (plus) and - (minus) sides of the subunits are identifi ed on the inner circumference of the channel. 
The location of the two GABA binding sites at the β2+α1- interfaces and the benzodiazepine (BZ) binding site 
at the α1+γ2- interface is indicated by arrows. The fi gure is a modifi cation of the fi gure in Ref 52. (B) Solvent 
accessible spaces contained in GABAA receptor transmembrane models. The view is from outside the cell with 
the extracellular domain invisible. The four transmembrane helical domains of each subunit are shown. Solvent 
accessible spaces are within each transmembrane four helical domaine (pale gray) as well as between helix 1 
of one subunit and helix 3 of the neighboring subunit (dark gray), as well as within the central ion channel 
(intermediate gray). (C) Dimer of the extracellular and transmembrane domaine of β and α subunits (GABA 
binding site) viewed from the outside of the pore. Solvent accessible spaces are within the extracellular interface 
(intermediate gray), within the continuation of this space in the transmembrane domaine between two four 
helix bundles (dark gray), within the four helix bundle of each subunit (pale gray). Figures (B) and (C) are 
modifi cations of fi gures shown in Ref. 54.
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was confi rmed by us and other groups using etomidate, propofol, or steroid 
derivatives that could be used for covalent labeling of amino acid residues 
located within the respective binding sites55,56,57,58.
We, however, were especially interested in the benzodiazepine binding 
site, because benzodiazepines had been used clinically for more than 50 years 
already and there was still no solid information on how these drugs bind into 
the benzodiazepine binding site of GABAA receptors. In the absence of a 
GABAA receptor crystal structure, we could only use structural models for 
the docking of benzodiazepines into the benzodiazepine binding site. At the 
time this work was started, however, multiple crystal structures of proteins 
were available that are homologous to the extracellular domain of the GABAA 
receptor. These structures were obtained from different snails (AChBP from 
lymnea stagnalis, aplysia californica), from the nicotinic acetylcholine receptor, 
from the bacteria Gloeobacter violaceus (GLIC) or Erwinia chrysanthemi (ELIC), 
or from the nematode Caenorhabditis elegans (GluCl), often co-crystallized with 
different ligands. Each one of these structures could be used as a template 
for modelling GABAA receptors. These proteins, however, differed in their 
homology to GABAA receptors and depending on the ligand bound, had 
different conformations. A single model thus could not cover the variability 
of all templates. 
55 Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB (2006) Identifi cation 
of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an 
etomidate analogue. J Neurosci 26, 11599-11605.
56 Chiara DC, Dostalova Z, Jayakar SS, Zhou X, Miller KW, Cohen JB (2012) Mapping general  
anesthetic binding site(s) in human α1β3 γ-aminobutyric acid type A receptors with [3H]
TDBzl-etomidate, a photoreactive etomidate analogue. Biochemistry 51, 836-847.
57 Chen ZW, Manion B, Townsend RR, Reichert DE, Covey DF, Steinbach JH, Sieghart W, 
Fuchs K, Evers AS (2012) Neurosteroid analogue photolabeling of a site in the TM3 domain of 
the β3 subunit of the GABAA receptor. Mol Pharmacol 82, 408-419. 
58 Yip GM, Chen ZW, Edge CJ, Smith EH, Dickinson R, Hohenester E, Townsend RR, Fuchs 
K, Sieghart W, Evers AS, Franks NP (2013) A propofol binding site on mammalian GABAA 
receptors identifi ed by photolabeling. Nature Chem Biol 9, 715-720.
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Margot Ernst, supported by Lars Richter, a gifted graduate student, 
therefore started to develop a novel docking procedure. Starting from 8 different 
crystal structures as templates and using multiple sequence alignments they 
ended up with 37 structural models of the extracellular domain of GABAA 
receptors. They then used the structure of the benzodiazepine diazepam for the 
selection of models suitable for docking: the two lipophilic regions of diazepam 
(the pendant phenyl ring and the annealed phenyl ring) had to be in lipophilic 
parts of the benzodiazepine pocket and diazepam had to have contacts with 
both subunits. Models not consistent with these requirements were eliminated. 
In a second step, 9 diazepam analogues with different substitutions at the ring 
system but with high affi nity for the benzodiazepine binding site were used 
in a similar way to further reduce the number of docking-suitable models 
to a total of six. The docking of 9 diazepam analogues into 6 models, using 
fl exible side chains and a lipophilic interaction above median resulted in a total 
of 1463 ligand poses in the benzodiazepine pocket that still could exhibit all 
orientations. After dividing these poses into 30 pose-clusters, only 3 clusters 
were identifi ed that accomodated all 9 ligands, thus resulting in 3 common 
binding modes. Only one of these was supported by all experimental results 
available from more than 20 years of research. After the identifi cation of the 
amino acid residues of the pocket in contact with the ligands, the fi rst model 
structures of the ligand-bound benzodiazepine binding site were obtained59 
(Fig 4).
These structures are no crystal structures but represent a cluster of poses 
from different models. Nevertheless, they can be used like crystal structures. 
From a correct structure one would expect that it should also be able to bind 
additional ligands of the benzodiazepine binding site representing different 
59 Richter L, de Graaf C, Sieghart W, Varagic Z, Mörzinger M, de Esch IJP, Ecker GF, Ernst 
M (2012) Diazepam-bound GABAA receptor models identify new benzodiazepine binding site 
ligands. Nature Chem Biol 8, 455-464.
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structural classes. Retrospective virtual drug screening with a large database 
of 93.597 drug structures that was spiked with 41 benzodiazepine binding 
site ligands from different structural classes resulted in 8 benzodiazepine site 
ligands in the top 1% and an enrichment factor over a random of 17.8. This 
enrichment factor was comparable to enrichment factors usually obtained with 
similar procedures from crystal structures. Further experiments will have to be 
performed to identify binding poses and conformations of the benzodiazepine 
pocket that are able to accomodate other ligands of the benzodiazepine binding 
site. But we also would have had to do that if we had started our docking 
from a crystal structure of a GABAA receptor. And such a structure is still 
not available. Nevertheless, this model structure is suitable for structure and 
fragment based drug design. This is indicated by a prospective docking based 
Figure 4: Representation of a diazepam docking pose within the benzodiazepine binding site, 
taken from Ref. 59.
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virtual screening using the same library, as well as by a fragment based virtual 
screening using another compound library, that identifi ed 3 structurally novel 
ligands of the benzodiazepine binding site that acted as positive allosteric 
modulators of GABAA receptors59.
Given the existence of at least 41 distinct structural classes of benzo-
diazepine binding site ligands it is currently not very rewarding to identify 
structurally novel ligands for this site, although such novel ligands might be 
more suitable than existing ones for specifi cally modulating GABAA receptor 
subtypes. Structural models of GABAA receptor subtypes, however, would 
be interesting targets for structure- and fragment-based drug design and could 
be used for a rapid development of drugs with an interesting preclinical and 
possibly also clinical action. The classical benzodiazepines such as diazepam 
exhibit a more or less similar positive allosteric modulation at all GABAA 
receptors composed of α1βγ2, α2βγ2, α3βγ2, or α5βγ2 subunits, and by that, 
mediate their anxiolytic, anticonvulsant, muscle relaxant, and sedative-
hypnotic actions. In the last 10 years the fi rst benzodiazepine site ligands have 
been developed that could distinguish between these different GABAA receptor 
subtypes. In addition, investigating the loss of in vivo diazepam action in GABAA 
receptor subunit knockout mice, or in mice in which a point mutation in the (+) 
side of various α subunits was introduced, which renders the respective receptors 
diazepam-insensitive, it is now clear that α1βγ2 receptors seem to mediate the 
sedative, anticonvulsant and anterograde amnestic properties of diazepam60,61. 
60 Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann 
H, Möhler H (1999) Benzodiazepine actions mediated by specifi c gamma-aminobutyric acid(A) 
receptor subtypes. Nature 401, 796-800. 
61 McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, 
Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore 
KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ (2000) Sedative 
but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 
subunit. Nat Neurosci 3, 587-592.
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Receptors composed of α2βγ2 predominantly mediate anxiolytic, muscle 
relaxant, and analgetic activity62, as do α3βγ2 receptors. The latter receptors, 
however, require higher receptor occupancy for their anxiolytic action63. 
The analgetic action of α2βγ2 and α3βγ2 receptors is based on the fact that 
these receptor types are located on intrinsic dorsal horn neurons, whereas 
α2βγ2 receptors are also expressed by primary afferents of the spinal cord64. 
Interestingly, there seems to be no tolerance development to these effects and 
thus, selectively enhancing the action of GABA at these receptor subtypes 
might fi nd a highly interesting clinical application. In addition, modulating 
α2βγ2 and/or α3βγ2 receptors might have benefi cial effects for the treatment of 
Down syndrome, affective disorders, schizophrenia and autism65. 
Receptors composed of α5βγ2 subunits again contribute to the myorelaxant 
action of diazepam but also are involved in regulating learning and memory. 
Mice, in which the α5 subunit has been deleted exhibit better cognitive abilities 
and learn better65. Negative allosteric modulators selective for α5-containing 
GABAA receptors are thus currently developed as cognition enhancers. In 
addition, Istvan Mody recently demonstrated that such compounds could also 
be benefi cial for reducing brain damage after stroke66.
This scheme of actions of different GABAA receptor subtypes for sure 
is oversimplifi ed. One cannot assume that a single receptor subtype is solely 
62 Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann 
H, Möhler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation 
of anxiety. Science 290, 131-134.
63 Möhler H (2011) The rise of a new GABA pharmacology. Neuropharmacol 60, 1042-1049.
64 Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, Brockhaus J, Sergejeva M, 
Hess A, Brune K, Fritschy JM, Rudolph U, Möhler H, Zeilhofer HU (2008) Reversal of 
pathological pain through specifi c spinal GABAA receptor subtypes. Nature 451, 330-334. 
65 Rudolph U, and Möhler H (2014) GABAA receptor subtypes: therapeutic potential in Down 
syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol 54, 483-507. 
66 Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST (2010) Reducing excessive 
GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 468, 305-309.
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responsible for the anxiolytic action of diazepam and for sure, other recep-
tor subtypes contribute to this action, and this has also been demonstrated in 
the last couple of years. Nevertheless, the receptor types indicated represent 
promising targets for eliciting the respective actions and it is thus worthwhile 
to develop appropriate receptor subtype-selective compounds. 
This was one of the reasons we started a collaboration with Jim Cook, 
University of Wisconsin, Milwaukee, USA in 2002. Jim Cook concentrates 
on the synthesis of classical benzodiazepines and imidazobenzodiazepines to 
make them more GABAA receptor subtype-selective. Due to the well-known 
extremely low toxicity of these compound classes, the risks of their failure in 
a clinical application are low. By investigating quite a few of the compounds 
synthesized by Jim Cook and his group, during the last 12 years we have 
identifi ed and helped to develop the compound HZ 166, that is a positive 
allosteric modulator highly selective for α2βγ2/α3βγ2 receptors67 (Fig 5A). It has 
been demonstrated to exhibit anxiolytic and much reduced sedative effects and 
is also active against neuropathic pain68,69.. Another compound, PWZ-029, is 
one of the most selective negative allosteric modulators at α5βγ2 receptors, and 
as expected, it enhances cognition70 (Fig 5B). 
67 Rivas FM, Stables JP, Murphree L, Edwankar RV, Edwankar CR, Huang S, Jain HD, Zhou 
H, Majumder S, Sankar S, Roth BL, Ramerstorfer J, Furtmüller R, Sieghart W, Cook JM 
(2009) Antiseizure activity of novel gamma-aminobutyric acid(A) receptor subtype-selective 
benzodiazepine analogues in mice and rat models. J Med Chem 52, 1795-1798.
68 Savic MM, Majumder S, Huang SM, Edwankar RV, Furtmüller R, Joksimovic S, Clayton T, 
Ramerstorfer J, Milinkovic MM, Roth BL, Sieghart W, and Cook JM (2010) Novel positive 
allosteric modulators of GABAA receptors: Do subtle differences in activity at α1 plus α5 ver-
sus α2 plus α3 subunits account for dissimilarities in behavioural effects in rats? Progr Neuro-
Psychopharmacol Biol Psychiatry 34, 376-386.
69 Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R, Cook JM, Zeilhofer 
HU (2011) HZ 166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is 
antihyperalgesic in mouse models of infl ammatory and neuropathic pain. Neuropharmacol 60, 
626-632.
70 Savic MM, Clayton T, Furtmüller R, Gavrilovic I, Samardzic J, Savic S, Huck S, Sieghart W, 
Cook JM (2008) PWZ-029, a compound with moderate inverse agonist functional selectivity 
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Recently, it has been demonstrated that airway smooth muscle cells 
contain only a restricted repertoire of GABAA receptor subunits, and that 
activating α4 or α5 subunit-containing receptors facilitates relaxation and 
reduces mucus formation71,72,, suggesting a novel therapeutic option for patients 
with severe bronchospasm. By investigating the action of a long series of Jim 
Cook´s compounds at various recombinant GABAA receptor subtypes we for 
the fi rst time developed positive allosteric modulators that are highly selective 
for α4βγ2 or α5βγ2 receptors and that are active in preventing mucus formation 
in bronchia and might have a possible application for the treatment of asthma 
(Emala, unpublished results). In addition, recently it has been demonstrated 
at GABAA receptors containing alpha5 subunits, improves passive, but not active avoidance 
learning in rats. Brain Res 1208, 150-159. 
71 Mizuta K, Xu D, Pan Y, Comas G, Sonett JR, Zhang Y, Panettieri RA Jr, Yang J, Emala CW 
Sr (2008) GABAA receptors are expressed and facilitate relaxation in airway smooth muscle. Am 
J Physiol Lung Cell Mol Physiol 294, L1206-1216.
72 Gallos G, Yim P, Chang S Zhang Y, XuD, Cook JM, Gerthoffer WT, Emala CW Sr (2012) 
Targeting the restricted α-subunit repertoire of airway smooth muscle GABAA receptors 
augments airway smooth muscle relaxation. Am J Physiol Lung Cell Mol Physiol 302, L248-256.
Figure 5: (A) Structural formula of the benzodiazepine HZ 166 and concentration-response curves of this 
compound at various recombinant receptor subtypes expressed in Xenopus laevis oocytes and measured by the 
two electrode voltage clamp technique. Data are from Ref 67. 
(B) Structural formula of the imidazobenzodiazepine PWZ-029 and concentration-response curves of this 
compound at various recombinant receptor subtypes expressed in Xenopus laevis oocytes and measured by the 
two electrode voltage clamp technique. Data are from Ref 70.
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that highly specifi c and potent α5-GABAA receptor agonists negatively 
regulate the very aggressive, MYC-driven, “group3” medulloblastomas73. We 
are continuing to investigate such compounds to identify novel treatment 
principles and to possibly develop clinically important drugs. 
In the last couple of years we have investigated whether the extracellular 
α+β- interface of GABAA receptors might also function as a drug binding 
site. Since this interface is homologous to the benzodiazepine binding site of 
GABAA receptors located at the α+γ2- interface (Fig. 3A), we argued that at 
least some of the benzodiazepine site ligands might also be able to bind at the 
α+β- interface. To avoid binding to the benzodiazepine binding site, receptors 
had to be investigated that were composed of α1 and β3 subunits only. Such 
receptors that have recently been identifi ed in the brain seem to be composed of 
2 α1 and 3 β3 subunits, and thus, contain two GABA binding sites at the β3+α1- 
interface, two α1+β3- interfaces and one β3+β3- interface. In a screen of >100 
benzodiazepine site ligands, the pyrazoloquinolinone CGS 9895 (Fig. 6A), which 
had been demonstrated previously to interact with the benzodiazepine binding 
site of GABAA receptors with high affi nity, was identifi ed to strongly modulate 
α1β3 GABAA receptors. To investigate whether this effect was mediated via the 
extracellular α1+β3- interface, a steric hindrance approach was applied. Several 
amino acid residues known to be located within the benzodiazepine binding 
site at the α1+ side, as well as β3- residues homologous to residues located at 
the γ2- interface within the benzodiazepine binding site, were mutated to 
cysteines. Mutations that did not signifi cantly change the properties of the 
receptor (GABA-induced current, CGS 9895 modulation) were then reacted 
with MTSEA-biotin, a cysteine reactive reagent, and possible changes in the 
73 Sengupta S, Weeraratne SD, Sun H, Phallen J, Rallapalli SK, Teider N, Kosaras B, Amani V, 
Pierre-Francois J, Tang Y, Nguyen B, Yu F, Schubert S, Balansay B, Mathios D, Lechpammer 
M, Archer TC, Tran P, Reimer RJ, Cook JM, Lim M, Jensen FE, Pomeroy SL, Cho YJ 
(2013) α5-GABAA receptors negatively regulate MYC-amplifi ed medulloblastoma growth. Acta 
Neuropathol 127, 593-603.
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effects of CGS 9895 were investigated. Covalent binding of MTSEA-biotin 
within the drug binding site should have prevented access of the drug to the 
receptor and by that, should have prevented the drug effect. This was actually 
the case, indicating that CGS 9895 mediates its effect via the extracellular 
α1+β3- interface74. In other experiments using α1β3γ2 receptors, CGS 9895 did 
not modulate GABA-induced currents at nM concentrations but at microM 
concentrations elicited a comparable current enhancement in α1β3 and α1β3γ2 
receptors. The effects of CGS 9895 on α1β3γ2 receptors in contrast to that of 
diazepam could not be inhibited by the benzodiazepine site antagonist Ro15-
1788, and 50 nM CGS 9895, a concentration that completely saturates the 
high affi nity benzodiazepine binding site of GABAA receptors, but does not 
74 Ramerstorfer J, Furtmüller R, Sarto-Jackson I, Varagic Z, Sieghart W, Ernst M (2011) The 
GABAA receptor α+β- interface: a novel target for subtype-selective drugs. J Neurosci 31, 870-
877.
Figure 6: (A) Structural formula of the pyrazoloquinolinone CGS 9895. (B) Structural formula of the 
pyrazoloquinolinone compound 6. (C) Concentration-response curves of compound 6 at various recombinant 
GABAA receptor subtypes containing β1 subunits and expressed in Xenopus laevis oocytes and measured by 
the two electrode voltage clamp technique. (D) Concentration-response curves of compound 6 at various 
recombinant GABAA receptor subtypes containing β2 subunits.(E) Concentration-response curves of 
compound 6 at various recombinant GABAA receptor subtypes containing β3 subunits. Data are from Ref 77.
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stimulate GABA-induced currents, was able to completely inhibit the effects 
of diazepam at α1β3γ2 receptors. These data indicate that CGS 9895 is an 
antagonist (null modulator) at the high affi nity benzodiazepine binding site at 
nM concentration and stimulates the receptor at microM concentrations via 
the α1+β3- interface74. 
What is the importance of this novel binding site? Drugs interacting with 
the α+β- site of GABAA receptors exhibit actions similar to benzodiazepines. 
They cannot directly activate GABAA receptors but can only allosterically 
modulate ongoing GABA-induced currents. Such drugs, thus, will exhibit low 
toxicity, similar to the benzodiazepines. Whereas benzodiazepines require the 
presence of a γ subunit for their action, an α+β- interface is present not only 
at αβγ, but also at αβ, αβδ, αβε, αβθ, αβπ receptors. Drugs indiscriminately 
interacting with all possible α+β- sites will thus exhibit a much broader action 
than the benzodiazepines and might be excellent anticonvulsants. However, 
drugs that selectively interact with a specifi c α(1−6)+β(1-3)- interface can 
address novel receptor subtypes. Whereas benzodiazepines predominantly 
interact with α(1−6)βγ2 receptors irrespective of the type of β subunit 
present in the receptor, α+β- site ligands can differentiate between α(1−6)βγ2 
receptors containing either β1, β2, or β3 subunits. Recent evidence indicates 
that αβγ2 receptors containing β1 subunits might mediate the sedative actions 
of benzodiazepines. Drugs activating any one of the α(1−6)β(2/3)γ2 receptors 
but avoiding modulation of αβ1γ2 receptors might thus combine the benefi cial 
actions of benzodiazepines with a loss of their sedative actions. Drugs 
interacting with the α+β- site of GABAA receptors will thus have novel and 
possibly important actions75.
75 Sieghart W, Ramerstorfer J, Sarto-Jackson I, Varagic Z, Ernst M (2012) A novel GABAA recep-
tor pharmacology: drugs interacting with the α+β- interface. Br J Pharmacol 166, 476-485.
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In the meantime, we have investigated >25 pyrazoloquinolinones and 
studied their receptor subtype selectivity76,77. Interestingly, one of these 
compounds is the fi rst highly selective positive allosteric modulator of α6β3γ2 
receptors, thus providing the proof of principle for the assumption that 
subtype-selective compounds acting via the α+β- site can be generated (Fig 6B). 
Compound 6 does not interact with α6β1γ2 receptors and only weakly interacts 
with α6β2γ2 receptors (Fig 6C-E), thus proving the concept that α+β- site 
drugs can distinguish between receptors containing different β subunit types. 
Previously known compounds exhibiting some selectivity for α6-containing 
GABAA receptors, such as the diuretics furosemide78 or amiloride79, or the 
dissociative anesthetic and NMDA receptor blocker ketamine80, are diffi cult 
to be used in animal experiments or man because of their additional actions at 
non-GABAergic systems. Compound 6 is currently used for the investigation 
of the function of α6 receptors in the brain. Recently, we have identifi ed highly 
interesting effects of this compound in an animal model of a human disease 
and the application of this compound for the treatment of this disease is the 
topic of a current patent application.
76 Varagic Z, Wimmer L, Schnürch M, Mihovilovic MD, Huang S. Rallapalli S, Cook JM, 
Mirheydari P, Ecker GF, Sieghart W, Ernst M (2013) Identifi cation of novel positive allosteric 
modulators and null modulators at the GABAA receptor α+β- interface. Br J Pharmacol 169, 371-
383.
77 Varagic Z, Ramerstorfer J, Huang S, Rallapalli S, Sarto-Jackson I, Cook J, Sieghart W, Ernst 
M (2013) Subtype selectivity of α+β- site ligands of GABAA receptors - identifi cation of the fi rst 
highly specifi c positive modulators at α6β2/3γ2 receptors. Br J Pharmacol 169, 384-399.
78 Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ (1996) Functional 
characterization of human gamma-aminobutyric acidA receptors containing the alpha4 
subunit. Mol Pharmacol 50, 670-678.
79 Drafts BC, Fisher JL (2004) Structural determinants of the pharmacological properties of the  
GABAA receptor alpha6 subunit. J Pharmacol Exp Ther 309, 1108-1115.
80 Hevers W, Hadley SH, Lüddens H, Amin J (2008) Ketamine, but not phencyclidine, selectively 
modulates cerebellar GABAA receptors containing alpha6 and delta subunits. J Neurosci 28, 5383-
5393.
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In summary, I have provided an overview of selected topics of our work 
performed during 35 years of GABAA receptor research. This work started with 
the [3H]fl unitrazepam photolabeling experiments of brain membranes leading 
to the fi rst identifi cation of distinct GABAA-benzodiazepine receptors in the 
brain. The generation of GABAA receptor subunit-selective antibodies then 
allowed to determine the subunit-composition of GABAA receptor subtypes 
and the heterogeneity of GABAA receptors turned out to be much larger 
than expected. The antibodies, however, were also used for the investigation 
of the regional, cellular and subcellular distribution of the subunits in the 
brain and thus, provided most of our current knowledge on GABAA receptor 
heterogeneity and location81. To identify receptors in situ and to determine 
their function in the brain, a careful pharmacological characterization of the 
receptors and the identifi cation of drugs selectively interacting with receptor 
subtypes are essential. Our work during the last couple of years has identifi ed 
compounds that are highly selective for α1βγ2, α2/3βγ2, α4βγ2, α5βγ2, or α6βγ2 
receptors. These compounds can now be used for investigating the function of 
the respective receptors in the brain and for studying their effects in various 
animal models of human diseases of the brain and of the periphery. It is clear 
now, that GABAA receptor subtypes can modulate anxiety, cognition, sleep, 
pain, epilepsy, stroke, schizophrenia, depression, and autism, as well as asthma, 
tumors, and possibly also diabetes. Drugs selectively modulating the receptor 
subtypes suitable for treating these diseases will thus become important for a 
variety of clinical applications. Our identifi cation and location of multiple drug 
binding sites in GABAA receptors combined with our modeling and docking 
studies opens the route for structure-based drug design and will accelerate the 
development of novel receptor subtype-selective drugs.
81 Olsen RW and Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes 
of γ-Aminobutyric AcidA Receptors: Classifi cation on the Basis of Subunit Composition, 
Pharmacology, and Function–Update. Pharmacol Rev 60: 243-260. 
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